Match each patient's preoperative medication profile with the most appropriate perioperative management strategy for that specific medication.
- A 61-year-old taking empagliflozin for type 2 diabetes, scheduled for an elective bowel resection.Discontinue 3 to 4 days prior to surgery.
- A 74-year-old taking lisinopril for hypertension, scheduled for an elective inguinal hernia repair.Withhold the dose specifically on the morning of surgery.
- A 58-year-old taking warfarin for a mechanical mitral valve, scheduled for a partial nephrectomy.Discontinue 5 days prior to surgery and bridge with low-molecular-weight heparin.
- A 65-year-old taking methotrexate for well-controlled rheumatoid arthritis, scheduled for a total joint arthroplasty.Continue the medication without interruption throughout the perioperative period.
- A 71-year-old taking rivaroxaban for nonvalvular atrial fibrillation, scheduled for an elective open abdominal surgery.Discontinue 2 to 3 days prior to surgery without initiating bridging therapy.
Cevap
Empagliflozin is stopped 3-4 days prior. Lisinopril is held the morning of surgery. Warfarin is stopped 5 days prior with LMWH bridging. Methotrexate is continued without interruption. Rivaroxaban is stopped 2-3 days prior without bridging.
Preoperative optimization requires individualized medication adjustments based on pharmacokinetics and surgical stress. SGLT2 inhibitors (empagliflozin) are stopped 3 to 4 days prior to avoid euglycemic DKA. ACE inhibitors (lisinopril) are held the morning of surgery to prevent severe vasoplegia. High-risk thromboembolic conditions (mechanical mitral valve) require warfarin cessation 5 days prior with LMWH bridging. DOACs (rivaroxaban) are held 2 to 3 days prior without bridging due to their rapid offset. Non-biologic DMARDs (methotrexate) are continued in stable rheumatoid arthritis to prevent disease flares that hinder recovery.
Adım Adım Çözüm
Anahtar Kavram
Optimal perioperative medication management involves balancing surgical risks (e.g., bleeding, hypotension, ketoacidosis) against the risk of underlying disease exacerbation.
Tahmini Süre:2m 0s